Matthew Kraman

Matthew Kraman

Auto-generated profile, based on publicly available information

Matthew Kraman

F-Star Biotechnology Ltd., Cambridge, United Kingdom

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 November 2013 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
CFChristine Feig
Christine Feig
JJJames O. Jones
James O. Jones
MKMatthew Kraman
Matthew Kraman
RWRichard J. B. Wells
Richard J. B. Wells
ADAndrew Deonarine
Andrew Deonarine
DFDouglas T. Fearon
Douglas T. Fearon
Significance: Cancer immune evasion is well described. In some cases, this may be overcome by enhancing T-cell responses. We show that despite the presence of antitumor T cells, immunotherapeutic antibodies are ineffective in a murine pancreatic cancer model recapitulating the human disease. Removing the carcinoma-associated fibroblast (CAF) expressing fibroblast activation protein (FAP) from tumors permitted immune control of tumor growth and uncovered the efficacy of these immunotherapeutic antibodies. FAP + CAFs are the only tumoral source of chemokine (C-X-C motif) ligand 12 (CXCL12), and administering AMD3100, an inhibitor of chemokine (C-X-C motif) receptor 4, a CXCL12 receptor, also revealed the antitumor effects of an immunotherapeutic antibody and greatly diminished cancer cells. These findings may have wide clinical relevance because FAP + cells are found in almost all human adenocarcinomas.

5 November 2010 in Science
Verified
Journal Article
Closed access
PDF file
MKMatthew Kraman
Matthew Kraman
PBPaul J. Bambrough
Paul J. Bambrough
JAJames N. Arnold
James N. Arnold
EREdward W. Roberts
Edward W. Roberts
LMLukasz Magiera
Lukasz Magiera
DFDouglas T. Fearon
Douglas T. Fearon
Tumor Vaccination Success: Vaccination with tumor-specific antigens is one of several attempted therapies seeking to harness the immune system, but—unfortunately—this strategy has been unsuccessful, possibly because of the immunosuppressive properties of the tumor microenvironment. Kraman et al. (p. 827 ; see the Perspective by Schreiber and Rowley ) have identified immunosuppressive cells of mesenchymal origin in mice comprising 2% of the tumor stromal cell population. They were identified by expression of the fibroblast activation protein–α. Deletion of these cells in lung or pancreatic cancers in mice allowed successful therapeutic vaccination against the tumors, which was dependent on the adaptive immune system and the cytokines interferon-γ and tumor necrosis factor–α. These findings reveal that multiple cell types contribute to the immunosuppressive tumor microenvironment and will inform therapeutic cancer vaccine design.

27 May 2013 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
EREdward W. Roberts
Edward W. Roberts
ADAndrew Deonarine
Andrew Deonarine
JJJames O. Jones
James O. Jones
ADAlice E. Denton
Alice E. Denton
CFChristine Feig
Christine Feig
DFDouglas T. Fearon
Douglas T. Fearon
Fibroblast activation protein-α (FAP) identifies stromal cells of mesenchymal origin in human cancers and chronic inflammatory lesions. In mouse models of cancer, they have been shown to be immune suppressive, but studies of their occurrence and function in normal tissues have been limited. With a transgenic mouse line permitting the bioluminescent imaging of FAP+ cells, we find that they reside in most tissues of the adult mouse. FAP+ cells from three sites, skeletal muscle, adipose tissue, and pancreas, have highly similar transcriptomes, suggesting a shared lineage. FAP+ cells of skeletal muscle are the major local source of follistatin, and in bone marrow they express Cxcl12 and KitL. Experimental ablation of these cells causes loss of muscle mass and a reduction of B-lymphopoiesis and erythropoiesis, revealing their essential functions in maintaining normal muscle mass and hematopoiesis, respectively. Remarkably, these cells are altered at these sites in transplantable and spontaneous mouse models of cancer-induced cachexia and anemia. Thus, the FAP+ stromal cell may have roles in two adverse consequences of cancer: their acquisition by tumors may cause failure of immunosurveillance, and their alteration in normal tissues contributes to the paraneoplastic syndromes of cachexia and anemia.

1 August 1996 in Nature Genetics
Verified
Journal Article
Closed access
SDSara C.M. Daw
Sara C.M. Daw
CTCatherine Taylor
Catherine Taylor
MKMatthew Kraman
Matthew Kraman
KCKathy Call
Kathy Call
JMJen-I Mao
Jen-I Mao
PSPeter Scambler
Peter Scambler

1 February 2014 in Cancer Immunology Research
Verified
Journal Article
Closed access
PDF file
JAJames N. Arnold
James N. Arnold
LMLukasz Magiera
Lukasz Magiera
MKMatthew Kraman
Matthew Kraman
DFDouglas T. Fearon
Douglas T. Fearon
The depletion of tumor stromal cells that are marked by their expression of the membrane protein fibroblast activation protein-α (FAP) overcomes immune suppression and allows an anticancer cell immune response to control tumor growth. In subcutaneous tumors established with immunogenic Lewis lung carcinoma cells expressing ovalbumin (LL2/OVA), the FAP+ population is comprised of CD45+ and CD45− cells. In the present study, we further characterize the tumoral FAP+/CD45+ population as a minor subpopulation of F4/80hi/CCR2+/CD206+ M2 macrophages. Using bone marrow chimeric mice in which the primate diphtheria toxin receptor is restricted either to the FAP+/CD45+ or to the FAP+/CD45− subset, we demonstrate by conditionally depleting each subset that both independently contribute to the immune-suppressive tumor microenvironment. A basis for the function of the FAP+/CD45+ subset is shown to be the immune inhibitory enzyme, heme oxygenase-1 (HO-1). The FAP+/CD45+ cells are the major tumoral source of HO-1, and an inhibitor of HO-1, Sn mesoporphyrin, causes the same extent of immune-dependent arrest of LL2/OVA tumor growth as does the depletion of these cells. Because this observation of immune suppression by HO-1 expressed by the FAP+/CD45+ stromal cell is replicated in a transplanted model of pancreatic ductal adenocarcinoma, we conclude that pharmacologically targeting this enzyme may improve cancer immunotherapy. Cancer Immunol Res; 2(2); 121–6. ©2013 AACR.

23 January 2009 in Science
Verified
Journal Article
Closed access
PDF file
OBOliver Bannard
Oliver Bannard
MKMatthew Kraman
Matthew Kraman
DFDouglas T. Fearon
Douglas T. Fearon
Models of the differentiation of memory CD8 + T cells that replicate during secondary infections differ over whether such cells had acquired effector function during primary infections. We created a transgenic mouse line that permits mapping of the fate of granzyme B (gzmB)–expressing CD8 + T cells and their progeny by indelibly marking them with enhanced yellow fluorescent protein (EYFP). Virus-specific CD8 + T cells express gzmB within the first 2 days of a primary response to infection with influenza, without impairment of continued primary clonal expansion. On secondary infection, virus-specific CD8 + T cells that became EYFP + during a primary infection clonally expand as well as all virus-specific CD8 + T cells. Thus, CD8 + T cells that have acquired an effector phenotype during primary infection may function as memory cells with replicative function.